Study of apatinib plus chemotherapy for recurrent childhood medulloblastoma
Part of Cancer clinical trials.
This trial tests whether adding apatinib to temozolomide and etoposide helps children whose medulloblastoma has come back. It aims to slow the tumor and improve outcomes after standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 2 to 21 at diagnosis, and have medulloblastoma confirmed by biopsy or surgery
- Have confirmed tumor recurrence on MRI (at least a 1 cm enhancing lesion seen across at least 2 slices)
- Finish prior radiation at least 4 weeks ago, and prior chemotherapy at least 4 weeks ago (and fully recovered
- Have enough strength/ability for treatment (KPS ≥50 if over 12, or Lansky ≥50 if 12 or younger)
- Have generally normal heart, lungs, liver, kidneys, blood counts, and clotting tests, with no active serious problems
- Be able to swallow capsules and agree to provide tumor tissue samples for the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether apatinib can shrink or control recurring atypical/malignant meningioma that has come back after surgery and radiation. It focuses on adults with measurable regrowth on MRI and good overall health to safely take an oral medicine.
This study tests whether the combination of two drugs, apatinib (a targeted therapy) and liposomal irinotecan (a chemotherapy), can help people with osteosarcoma that has not responded to standard treatments or has spread. The goal is to see if the combination can shrink tumors or slow the disease.
This trial tests a combination of four drugs (chidamide, dinutuximab beta, irinotecan, and temozolomide) for children whose neuroblastoma has returned or isn't responding to standard treatment. It aims to see if this mix can shrink the tumor or stop it from growing.
This trial tests two drugs, axitinib and etoposide, taken by mouth to treat children and young adults with medulloblastoma or ependymoma that has returned or not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of antiangiogenic drugs (which block blood supply to tumors) for children with certain brain or spinal tumors that have returned or not responded to standard treatment. The goal is to see if this drug combo can shrink or slow the tumor.
This trial tests a new medicine (RVU120) combined with an existing drug (everolimus) in children whose medulloblastoma (a type of brain tumor) has come back or gotten worse. The goal is to see if this combination can help stop the tumor from growing.
Hear when a new Recurrent Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.